MedTrace Logo

Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

NCT06783166 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-01-20

No results posted yet for this study

Summary

This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.

Conditions

  • Acute Heart Failure

Interventions

DRUG

Dapagliflozin 10mg

Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

DRUG

Acetazolamide 500mg

Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Noha Mansour, PhD · Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura

  • Moheb Magdy Mouris, MD · Department of Cardiology, Faculty of Medicine, University of Mansoura

  • Mohamed El- Husseiny Shams, Professor · Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2025-07-01
Completion
2025-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783166 on ClinicalTrials.gov